TRDA Entrada Therapeutics, Inc.
Price Chart
Executive Summary
Entrada Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Stockholders approved amendments to the company's 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan to include pre-funded warrants in the evergreen share calculation. Two Class II directors were elected and Ernst & Young was ratified as auditor. This is a routine governance filing with no material financial impact.
Actionable Insight
No actionable trading signal. This is a standard post-annual meeting filing with routine director elections and equity plan amendments. Monitor for operational or pipeline updates from upcoming earnings or press releases.
Key Facts
- Stockholders approved Amendment No. 1 to the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan, adding pre-funded warrants to the evergreen formula's outstanding share count.
- Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were elected as Class II directors.
- Ernst & Young LLP was ratified as independent auditor for fiscal year 2026.
- 38,820,616 shares outstanding as of record date April 13, 2026; 33,190,234 shares present at meeting.
- The 2021 Plan Amendment passed with 14,686,713 for, 9,566,186 against; the ESPP Amendment passed with 16,780,217 for, 7,475,514 against.
Financial Impact
No financial impact. The equity plan amendments are administrative and do not change share reserve amounts or dilutive limits directly.
Risk Factors
- No material risks identified in this filing.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-072326 |
| Document: tm2617532d1_ex10-1.htm | 0001104659-26-072326 |
| Document: tm2617532d1_ex10-2.htm | 0001104659-26-072326 |
| Document: 0001104659-26-072326-index-headers.html | 0001104659-26-072326 |
| Document: 0001104659-26-072326-index.html | 0001104659-26-072326 |
| Document: 0001104659-26-072326.txt | 0001104659-26-072326 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
8-K
| $5.96 awaiting T+1 | awaiting T+1 | — | $6.46 (+8.39%) |
|
Jun 2, 2026
11d ago
|
Press Release
| $6.64 $6.58 | ▼ −0.90% | ▼ −0.18% | $6.46 (−2.71%) |
|
May 7, 2026
5w ago
|
Press Release
| $6.85 $6.84 | ▼ −0.15% | ▼ −0.98% | $6.46 (−5.69%) |
|
May 4, 2026
5w ago
|
144
| $15.75 $16.03 | ▲ +1.78% | ▲ +0.39% | $6.46 (−58.98%) |
|
May 4, 2026
5w ago
|
Insider Cluster
| $15.79 $15.75 | ▲ +0.25% | ▲ +1.05% | $6.46 (+59.09%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $12.63 $12.96 | ▲ +2.61% | ▲ +2.45% | $6.46 (−48.85%) |
|
Mar 4, 2026
14w ago
|
Insider Cluster
| $12.50 $11.62 | ▼ −7.04% | ▼ −6.47% | $6.46 (−48.32%) |
|
Feb 26, 2026
15w ago
|
8-K
| $12.79 $11.93 | ▲ +6.72% | ▲ +6.27% | $6.46 (+49.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access